Clinical trials: CMV Infection
Infections, Cytomegalovirus
Evaluation of the Long-term Persistence of GlaxoSmithKline (GSK) Biologicals' Candidate Cytomegalovirus (CMV) Vaccine
The purpose of this study is to evaluate the persistence of the vaccine induced immune responses at Month 48 (Year 4) and Month 60 (Year 5) in healthy subjects who received 3 doses of GSK Biologicals' candidate CMV vaccine…
- Trial name
- NCT01357915
- Testing
- Blood sampling, GSK149203A
- Where
- 2 sites in Belgium
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cytomegalovirus (CMV)
A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection
The main aim of the study is to check if maribavir can treat Japanese people with Cytomegalovirus (CMV) infection, and to check side effect from the study treatment and how much maribavir participants can take without getting…
- Trial name
- NCT05137717
- Testing
- Maribavir
- Where
- 20 sites in Japan
- Volunteers
- 41 people
- Sponsor
- Takeda
Cytomegalovirus Infections
An Observational Study of Valcyte (Valganciclovir) in D+/R- Liver Transplant Recipients
This retrospective review will evaluate the efficacy of Valcyte (valganciclovir) in preventing Cytomegalovirus (CMV) disease in D+/R- liver transplant recipients.
- Trial name
- NCT02062294
- Where
- 3 sites in Switzerland
- Volunteers
- 14 people
- Sponsor
- Hoffmann-La Roche
Cytomegalovirus Infections, HIV Infections
Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)
A5355 was a randomized, placebo-controlled study conducted at US sites to evaluate the safety and immunogenicity of two injections of the study drug Modified Vaccinia Ankara (MVA)-based anti-Cytomegalovirus (CMV) Vaccine…
- Conditions
- Cytomegalovirus Infections, HIV Infections, Vaccine
- Trial name
- NCT05099965
- Testing
- CMV-MVA Triplex
- Where
- 12 sites in United States
- Volunteers
- 94 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
CMV, Congenital Cmv
Cytomegalovirus Shedding Characteristics in Pregnant Women
The cCHIPS study is a feasibility study for larger scale multi-centre studies and is designed as a single-centre observational cohort, longitudinal, natural history study.
- Conditions
- CMV, Congenital Cmv, Maternal Infections Affecting Fetus or Newborn, Shedding Virus
- Trial name
- cCHIPS (NCT04021628)
- Testing
- No intervention- not applicable
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- St George's, University of London
Acute Lung Injury, Acute Respiratory Distress Syndrome
Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure
To evaluate whether administration of ganciclovir reduces serum IL-6 levels (i.e. reduction between baseline and 14 days post-randomization) in immunocompetent adults with severe sepsis or trauma associated respiratory failure.
- Conditions
- Acute Lung Injury, Acute Respiratory Distress Syndrome, Respiratory Failure
- Trial name
- GRAIL (NCT01335932)
- Testing
- IV Ganciclovir
- Where
- 14 sites in United States
- Volunteers
- 160 people
- Sponsor
- Fred Hutchinson Cancer Center
Cytomegalovirus Infection
A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)
The purpose of this study is to evaluate the efficacy and safety of a once-a-day oral or intravenous (IV) dose of Letermovir (MK-8228) in Chinese adult hematopoietic stem cell transplant (HSCT) recipients for the prevention of…
- Trial name
- NCT05763823
- Testing
- Letermovir
- Where
- 21 sites in China
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
Cytomegalovirus Infections
Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients
The purpose of this research study is to investigate whether or not oral maribavir is safe and effective compared to oral ganciclovir for preventing CMV disease when administered for up to 14 weeks in patients who have had a…
- Trial name
- NCT00497796
- Testing
- maribavir, ganciclovir
- Where
- 55 sites in United States
- Volunteers
- 307 people
- Sponsor
- Shire
HIV Infections, Cytomegalovirus Infections
Valganciclovir to Reduce T Cell Activation in HIV Infection
The purpose of this study is to determine whether treatment with valganciclovir decreases T cell activation levels among HIV-infected patients with asymptomatic cytomegalovirus (CMV) co-infection, potentially improving immune…
- Trial name
- NCT00264290
- Testing
- Valganciclovir
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Cytomegalovirus Infection
CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")
This is a trial of preemptive therapy vs. prophylaxis for prevention of Cytomegalovirus (CMV) disease in R-D+ liver transplant patients.
- Trial name
- NCT01552369
- Testing
- Valganciclovir
- Where
- 6 sites in United States
- Volunteers
- 205 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Cytomegalovirus Retinitis
Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT)
To evaluate the relative safety and efficacy of ganciclovir and foscarnet as initial treatment of patients with cytomegalovirus (CMV) retinitis.
- Trial name
- FGCRT (NCT00000136)
- Testing
- Foscarnet, Ganciclovir
- Volunteers
- 234 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Cytomegalovirus Infections
Evaluation of the Artus® CMV PCR Test
Subjects with symptomatic CMV infection, who are enrolled in this clinical study, will be monitored during antiviral therapy.
- Trial name
- CMV (NCT01034709)
- Where
- 5 sites in United States
- Volunteers
- 111 people
- Sponsor
- QIAGEN Gaithersburg, Inc
Cytomegalovirus Infections
A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults
The purpose of this study is to assess the safety, reactogenicity and immune response of the candidate CMV recombinant protein subunit (CMVsu) vaccine consisting of a combination of glycoproteins B (gB) and pentamer antigens…
- Trial name
- NCT05089630
- Testing
- Pentamer (low)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(low)/Adjuvant vaccine, Pentamer (med)/gB(med)/Adjuvant vaccine
- Where
- 18 sites in United States
- Volunteers
- 333 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Adenovirus Infection, BK Virus Infection
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
This is a Phase 3 study to evaluate posoleucel (ALVR105, Viralym-M); an allogeneic, off-the-shelf multi-virus specific T cell therapy that targets six viral pathogens: BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus…
- Conditions
- Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Trial name
- Prevent (NCT05305040)
- Testing
- Posoleucel (ALVR105)
- Where
- 88 sites in United States, Australia and 8 more
- Volunteers
- 451 people
- Sponsor
- AlloVir
Cytomegalovirus Infection
Dried Blood Spot Testing of CMV Detection in HCT Recipients
This is a randomized clinical trial to assess whether a subject centered, self-collection of Dried blood spots (DBS) samples will improve compliance with the clinical recommendation of weekly Cytomegalovirus (CMV) testing of…
- Trial name
- NCT03910478
- Testing
- DBS Self-Collection Kit, Standard Control Strategy
- Where
- 4 sites in United States
- Volunteers
- 622 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Disease, Cytomegalovirus Infections
Letermovir Use in Heart Transplant Recipients
This is an open label trial in which letermovir will be given as prophylaxis for the prevention of cytomegalovirus (CMV) infection and disease to all heart transplants who are at risk for cytomegalovirus.
- Conditions
- Cytomegalovirus Disease, Cytomegalovirus Infections, Heart Transplant Infection, Antiviral Toxicity
- Trial name
- NCT04904614
- Testing
- Letermovir
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Tufts Medical Center
Prevention of CMV Infection or Disease
Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001)
The study evaluated the efficacy and safety of letermovir (MK-8228) for the prevention of clinically-significant CMV infection in adult, CMV-seropositive recipients of allogeneic hematopoietic stem cell transplant (HSCT).
- Trial name
- NCT02137772
- Testing
- Letermovir
- Volunteers
- 570 people
- Sponsor
- Merck Sharp & Dohme LLC
Cytomegalovirus Disease, Kidney Transplant Infection
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
This was a randomized, double-blind, double-dummy, parallel-group, multicenter study of the efficacy, safety, and tolerability of oral brincidofovir (BCV) versus valganciclovir for the prevention of cytomegalovirus (CMV) disease…
- Trial name
- NCT02439957
- Testing
- Brincidofovir, Valganciclovir
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Jazz Pharmaceuticals
Cytomegalovirus Retinitis, HIV Infections
Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)
To compare the newest CMV retinitis drug, cidofovir, with a regimen of the ganciclovir intraocular device plus oral ganciclovir with respect to efficacy in preventing vision loss.
- Trial name
- GCCRT (NCT00000143)
- Testing
- Ganciclovir implant and oral ganciclovir, Cidofovir intravenous
- Where
- 19 sites in United States
- Volunteers
- 61 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
Cytomegalovirus Infection
Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss
This is an international, multi-center, double-blind, placebo-controlled evaluation valganciclovir treatment for up to 54 children (up to 4 years of age) with virologically-confirmed congenital CMV infection and hearing loss.
- Trial name
- NCT01649869
- Testing
- Valganciclovir
- Where
- 18 sites in United States, United Kingdom
- Volunteers
- 54 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)